Callio Therapeutics launches with US$187 Million series A to advance multi-payload ADC platform through clinical proof-of-concept

CAR-T Digest - August 2020

Weekly Digest - March 2025

03 March 2025: Callio Therapeutics launches with US$187 Million series A to advance multi-payload Antibody-Drug Conjugate platform through clinical proof-of-concept

Callio Therapeutics launches with $187M Series A financing led by Frazier Life Sciences, joined by Jeito Capital, Novo Holdings, and others
The company focuses on multi-payload ADCs to enhance cancer therapy, with headquarters in Seattle and Singapore
Funds will support clinical proof-of-concept for a HER2-targeted dual-payload ADC and a second undisclosed ADC program
Callio secures an exclusive global license from Hummingbird Bioscience for its multi-payload ADC platform and related assets
The agreement includes equity, potential milestone payments, and royalties for Hummingbird Bioscience combination